Lamivudine in preventing liver damages and HBV reactivation in anti-HBc positive lymphoma patients during chemotherapy
10.3760/cma.j.issn.1674-2397.2011.01.005
- VernacularTitle:抗-HBc阳性淋巴瘤患者化疗期间应用拉米夫定抗病毒治疗预防肝功能损害和HBV激活
- Author:
Chunxian PENG
;
Fenzhi WU
;
Xiaoyan ZHENG
;
Dan SHEN
;
Hangping YAO
;
Jian FAN
- Publication Type:Journal Article
- Keywords:
Lymphoma;
Lamivudine;
Hepatitis virus B;
Hepatitis B core antibody
- From:
Chinese Journal of Clinical Infectious Diseases
2011;04(1):25-28
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effectiveness of lamivudine in preventing liver damages and HBV DNA reactivation in anti-HBc positive lymphoma patients after chemotherapy.Methods Seventy-nine lymphoma patients who were negative in HBsAg and positive in anti-HBc were enrolled and were divided into lamivudine group (n=37) and control group (n=42).Both groups received chemotherapy.Liver damages and HBV reactivation were observed, and the data were analyzed with software SPSS 13.0.Results In lamivudine group, liver damages Ⅰ or Ⅱ was observed in 11 patients (11/37, 29.7%), and liver damages Ⅲ or Ⅳ was observed in 2 (2/37, 5.4%); two patients (2/37, 5.4%) developed HBV reactivation, and both of them had HBV YMDD mutations.In control group, 19 (19/42, 45.2%) patients experienced liver damages Ⅰ or Ⅱ, 7 (7/42, 16.7%) experienced liver damages Ⅲ or Ⅳ; 12 (12/42, 28.6%) patients experienced HBV reactivation, the differences between the two groups were of statistical significance (χ2=79.0, 8.7 and 79.0, P ＜ 0.05 or ＜ 0.01).Conclusion Lamivudine can reduce liver damages and HBV reactivation in HBsAg negative and anti-HBc positive patients with lymphoma during chemotherapy.
